179 related articles for article (PubMed ID: 30565580)
1. [Not all pains are the same: breakthrough pain in cancer patients. A case report].
Gunnellini M
Recenti Prog Med; 2018 Nov; 109(11):6e-10e. PubMed ID: 30565580
[TBL] [Abstract][Full Text] [Related]
2. [Breaktrough cancer pain in metastatic prostate adenocarcinoma: a case report.].
Santeufemia DA; Miolo G
Recenti Prog Med; 2019 Mar; 110(3):3e-5e. PubMed ID: 30968857
[TBL] [Abstract][Full Text] [Related]
3. Barriers to the use of buccal and intranasal fentanyl for breakthrough pain in paediatric palliative care: an exploratory survey.
Harrop E; Jamieson L; Choy TH; Ho WHP; Wong ICK
BMJ Support Palliat Care; 2018 Sep; 8(3):355-356. PubMed ID: 28801316
[No Abstract] [Full Text] [Related]
4. [Transmucosal fentanyl and breakthrough pain: The other side of the coin].
Henche Ruiz AI
Rev Esp Geriatr Gerontol; 2020; 55(1):56-57. PubMed ID: 31307779
[No Abstract] [Full Text] [Related]
5. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
[TBL] [Abstract][Full Text] [Related]
6. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough cancer pain: review and calls to action to improve its management.
Camps Herrero C; Batista N; Díaz Fernández N; Escobar Álvarez Y; Gonzalo Gómez A; Isla Casado D; Salud A; Terrasa Pons J; Guillem Porta V
Clin Transl Oncol; 2020 Aug; 22(8):1216-1226. PubMed ID: 32002739
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
[TBL] [Abstract][Full Text] [Related]
9. Use of oral formulations of fentanyl for breakthrough cancer pain.
Handsaker S; Dempsey L; Fabby C
Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
[No Abstract] [Full Text] [Related]
10. The management of wound-related procedural pain (volitional incident pain) in advanced illness.
Gallagher R
Curr Opin Support Palliat Care; 2013 Mar; 7(1):80-5. PubMed ID: 23150425
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
12. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Alberts DS; Smith CC; Parikh N; Rauck RL
Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
[TBL] [Abstract][Full Text] [Related]
14. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Überall MA
MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
[TBL] [Abstract][Full Text] [Related]
15. Opioid manufacturer bribed doctors to prescribe fentanyl inappropriately, US says.
Dyer O
BMJ; 2016 Dec; 355():i6742. PubMed ID: 27979812
[No Abstract] [Full Text] [Related]
16. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study.
Guitart J; Vargas MI; De Sanctis V; Folch J; Salazar R; Fuentes J; Coma J; Ferreras J; Moya J; Tomás A; Estivill P; Rodelas F; Jiménez AJ; Sanz A
Drugs R D; 2017 Sep; 17(3):419-425. PubMed ID: 28744772
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
[TBL] [Abstract][Full Text] [Related]
19. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
Núñez-Olarte JM; Alvarez-Jiménez P
J Pain Symptom Manage; 2011 Dec; 42(6):e6-8. PubMed ID: 22048003
[No Abstract] [Full Text] [Related]
20. The use of rapid onset fentanyl in children and young people for breakthrough cancer pain.
Coombes L; Burke K; Anderson AK
Scand J Pain; 2017 Oct; 17():256-259. PubMed ID: 29229211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
